» Articles » PMID: 20470757

PGE2 Inhibits Natural Killer and Gamma Delta T Cell Cytotoxicity Triggered by NKR and TCR Through a CAMP-mediated PKA Type I-dependent Signaling

Overview
Date 2010 May 18
PMID 20470757
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer (NK) and unconventional gammadelta T cells, by their ability to sense ligands induced by oncogenic stress on cell surface and to kill tumor cells without a need for clonal expansion, show a great therapeutic interest. They use numerous activating and inhibitory receptors which can function with some independence to trigger or inhibit destruction of target cells. Previous reports demonstrated that PGE(2) is able to suppress the destruction of some tumor cell lines by NK and gammadelta T cells but it remained uncertain if PGE(2) interferes with the different activating receptors governing the cytolytic responses of NK and gammadelta T cells. In this report, using the model of specific redirected lysis of the mouse FcgammaR(+) cell line P815, we clearly demonstrate that the major NK receptors (NKR): NKG2D, CD16 and natural cytotoxicity receptors (NCR: NKp30, NKp44, NKp46) and gammadelta T cell receptors TCR Vgamma9Vdelta2, NKG2D and CD16 are all inhibited by PGE(2). As is the case with gammadelta T cells, we show that PGE(2) binds on E-prostanoid 2 (EP2) and EP4 receptors on NK cells. Finally, we delineate that the signaling of the blockade by PGE(2) is mediated through a cAMP-dependent activation of PKA type I which inhibits early signaling protein of cytotoxic cells. In the discussion, we focused on how these data should impact particular approaches in the treatment of cancer.

Citing Articles

Expression of and as potential biomarkers in chronic myeloid leukemia patients in Brazil.

Kubaski Benevides A, Marin A, Wosniaki D, Oliveira R, Koerich G, Kusma B Front Oncol. 2024; 14:1443346.

PMID: 39450252 PMC: 11499243. DOI: 10.3389/fonc.2024.1443346.


Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective.

Liu J, Bai Y, Li Y, Li X, Luo K EBioMedicine. 2024; 107:105301.

PMID: 39178747 PMC: 11388279. DOI: 10.1016/j.ebiom.2024.105301.


Research progress on nonsteroidal anti-inflammatory drugs in the treatment of pituitary neuroendocrine tumors.

Li J, Shi X, Tang T, Zhou M, Ye F Front Pharmacol. 2024; 15:1407387.

PMID: 39135798 PMC: 11317762. DOI: 10.3389/fphar.2024.1407387.


Strategies for Overcoming Immune Evasion in Bladder Cancer.

Shin J, Park J, Kim S, Lee J, Choi W, Kim H Int J Mol Sci. 2024; 25(6).

PMID: 38542078 PMC: 10970137. DOI: 10.3390/ijms25063105.


cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment.

Zhang H, Liu Y, Liu J, Chen J, Wang J, Hua H J Hematol Oncol. 2024; 17(1):5.

PMID: 38233872 PMC: 10792844. DOI: 10.1186/s13045-024-01524-x.